Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne .

Catabasis Pharmaceuticals
TypePublic
NASDAQ: CATB
Russell Microcap Index component
IndustryPharmaceuticals
HeadquartersCambridge, Massachusetts
Key people
Jill C. Milne, Ph.D. (CEO)

Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer)

Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer)
ProductsOrally-delivered pharmaceuticals
Number of employees
24 (March 2019)
Websitewww.catabasis.com

In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values .


References
  1. "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.